GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.
GLORIA is funded by the EU Horizon 2020 Program. >>
Our article entitled "Patients’ and rheumatologists’ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study" has just been published by Oxford University Press.
Please click on the following link to view the abstract:
https://academic.oup.com/rheumatology/article-abstract/60/7/333 Read more
This study 'was undertaken to evaluate whether the proportion of included elderly individuals (PE) is independently associated with participant retention in rheumatology trials.'
Please click here for more information or here to access the full PDF.
A recent article with the title "Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial" has been recently published on the Scandinavian Journal of Rheumatology and we are proud to provide you with the PDF file. Just click here to view or download.